Muchtar, Eli http://orcid.org/0000-0003-2210-2174
Gertz, Morie A.
Kourelis, Taxiarchis V.
Sidana, Surbhi http://orcid.org/0000-0003-3288-7614
Go, Ronald S. http://orcid.org/0000-0002-8284-3495
Lacy, Martha Q.
Buadi, Francis K.
Dingli, David
Hayman, Suzanne R.
Kapoor, Prashant
Leung, Nelson http://orcid.org/0000-0002-5651-1411
Fonder, Amie
Hobbs, Miriam
Lisa Hwa, Yi
Gonsalves, Wilson
Warsame, Rahma
Russell, Stephen
Lust, John A.
Lin, Yi
Zeldenrust, Steven
Rajkumar, S. Vincent
Kyle, Robert A.
Kumar, Shaji K. http://orcid.org/0000-0001-5392-9284
Dispenzieri, Angela
Article History
Received: 3 July 2019
Revised: 23 October 2019
Accepted: 13 November 2019
First Online: 22 November 2019
Change Date: 29 July 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-020-0993-8
Compliance with ethical standards
:
: EM: None; MAG: Consultancy (Milleniu) and honoraria (Celgene, Millenium, Onyx, Novartis, Smith Kline, Prothena, Ionis). TVK: None; SS: None; RSG: None; MQL: Research funding (Celgene); FB: None; DD: Research funding (Karyopharm Therapeutics, Amgen, and Millenium Pharmaceuticals); SRH: None; PK: Research funding (Takeda, Celgene, and Amgen); NL: None; AF: None; MH: None; YLH: None; WG: None; RW: None; SR: None; JAL: None; YL: None; SZ: None; SVR: None; RAK: None; SKK: Consultancy (Celgene, Millennium, Onyx, Janssen, and BMS); and research funding (Celgene, Millennium, Novartis, Onyx AbbVie, Janssen, and BMS). AD: Research funding (Celgene, Millennium, Pfizer, and Janssen), Travel grant (Pfizer).